ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 22 Issue : 5
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Selective implantation of cardioverter-defibrillators in patients with genetic heart disease and sudden death risk [Anatol J Cardiol]
Anatol J Cardiol. 2009; 9(Suppl 2): 32-40

Selective implantation of cardioverter-defibrillators in patients with genetic heart disease and sudden death risk

The implantable cardioverter-defibrillator (ICD) therapy is an established intervention for the prevention of sudden cardiac death (SCD) in patients with significant left ventricular dysfunction. Multiple randomized clinical trials have studied the use of ICD for the primary and secondary SCD. These studies were performed in patients with left ventricular dysfunction from coronary artery disease or dilated cardiomyopathy, and the marker of reduced ejection fraction has emerged for selecting patients who would benefit from ICD therapy. Currently, for most of these patients the decision to implant, or not, is determined by relatively straightforward paradigms. The same cannot be said for the genetic cardiac diseases associated with SCD - long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular dysplasia. Indications for ICD in these conditions are very much a work-in-progress.

Keywords: Long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, implanted cardioverter-defibrillator


. Selective implantation of cardioverter-defibrillators in patients with genetic heart disease and sudden death risk. Anatol J Cardiol. 2009; 9(Suppl 2): 32-40


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright 2018 Turkish Society of Cardiology